Sunflower Pharmaceutical Group (002737) Fair Value & Analysis

Healthcare · CN · Market cap 7.2B CNY

Analysis

Sunflower Pharmaceutical Group (002737) currently trades at ¥11.98, while our model-based Fair Value estimate is ¥14.30 — implying the stock looks roughly 19.4% undervalued today. We read business quality at 91/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium) — always confirm before acting.

About the company

Sunflower Pharmaceutical Group Co.,Ltd engages in the research and development, manufacturing, and marketing of Chinese patent medicines in China and internationally. The company produces chemical and biological medicines, and health care products. It also provides products covering various therapeutic areas, including pediatrics, gynecology, adult digestive system, respiratory and cold, rheumatic bone disease, and cardiovascular and cerebrovascular; supplements; tonic; and antibiotics and children's medicinal products. The company sells its products under the Sunflower and Little Sunflower brands. Sunflower Pharmaceutical Group Co.,Ltd was founded in 2005 and is based in Harbin, China.

Open the full interactive analysis →

Similar stocks

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.